Stock TNYA TENAYA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Real-time Estimate Cboe BZX
Other stock markets
 14:12:27 2024-05-02 EDT 		5-day change 1st Jan Change
4.65 USD -0.64% Intraday chart for Tenaya Therapeutics, Inc. +9.95% +43.21%
03-20 Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating MT
03-19 North American Morning Briefing : Stock Futures -2- DJ

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating
MT
Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $17 From $18, Keeps Buy Rating
MT
Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $14 From $13, Keeps Overweight Rating
MT
Chardan Trims Price Target on Tenaya Therapeutics to $23 From $24, Maintains Buy Rating
MT
HC Wainwright Adjusts Price Target on Tenaya Therapeutics to $18 From $25, Maintains Buy Rating
MT
Chardan Cuts Price Target on Tenaya Therapeutics to $24 From $28, Keeps Buy Rating
MT
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data
RE
Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $13 From $15, Maintains Overweight Rating
MT
Chardan Trims Price Target on Tenaya Therapeutics to $28 From $30, Affirms Buy Rating
MT
Canaccord Genuity Starts Tenaya Therapeutics at Buy With $21 Price Target
MT
Chardan Research Trims Tenaya Therapeutics' Price Target to $30 From $31, Maintains Buy Rating
MT
HC Wainwright Starts Tenaya Therapeutics at Buy With $25 Price Target
MT
Morgan Stanley Lowers Tenaya Therapeutics' Price Target to $15 From $19, Maintains Overweight Rating
MT
Morgan Stanley Adjusts Tenaya Therapeutics' Price Target to $19 from $31, Keeps Overweight Rating
MT
TENAYA THERAPEUTICS : Chardan Starts Tenaya Therapeutics at Buy with $37 Price Target on Heart Disease Drugs' Potential
MT
TENAYA THERAPEUTICS : Cowen Starts Tenaya Therapeutics at Outperform
MT
TENAYA THERAPEUTICS : Morgan Stanley Initiates Coverage on Tenaya Therapeutics With Overweight Rating, $31 Price Target
MT
TENAYA THERAPEUTICS : Piper Sandler Starts Tenaya Therapeutics at Overweight With $40 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TNYA Stock
  4. News Tenaya Therapeutics, Inc.
  5. Analyst Reco.